| 2022-07-12 |
详情>>
内部人交易：
Marrone Pamela G等共交易23笔
|
| 2022-06-09 |
股东大会：
将于2022-07-08召开股东大会
会议内容 ▼▲
- 1.To adopt the Agreement and Plan of Merger, dated as of March 16, 2022 (which, as it may be amended from time to time, we refer to as the “merger agreement”), among BIOX, BCS Merger Sub, Inc. (which we refer to as “Merger Sub”) and MBI (which we refer to as the “merger proposal”).
2.To approve, by a non-binding advisory vote, certain compensation that may be paid or become payable to MBI’s named executive officers that is based on or otherwise relates to the merger contemplated by the merger agreement (which we refer to as the “non-binding compensation advisory proposal”).
3.To consider and vote on a proposal to approve the adjournment of the special meeting from time to time, if necessary or appropriate, to solicit additional proxies in favor of the merger proposal if there are insufficient votes at the time of such adjournment to approve such proposal (the “adjournment proposal”).
|
| 2022-06-09 |
详情>>
股本变动：
变动后总股本18237.82万股
|
| 2022-05-13 |
详情>>
业绩披露：
2022年一季报每股收益-0.04美元,归母净利润-759.6万美元,同比去年增长-132.93%
|
| 2022-05-11 |
财报披露：
美东时间 2022-05-11 盘后发布财报
|
| 2022-05-09 |
详情>>
业绩披露：
2021年年报每股收益-0.09美元,归母净利润-1655.4万美元,同比去年增长17.92%
|
| 2021-11-10 |
详情>>
业绩披露：
2021年三季报(累计)每股收益-0.06美元,归母净利润-1124.1万美元,同比去年增长29.55%
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-08-16 |
详情>>
业绩披露：
2021年中报每股收益-0.04美元,归母净利润-629.6万美元,同比去年增长36.37%
|
| 2021-05-13 |
详情>>
业绩披露：
2021年一季报每股收益-0.02美元,归母净利润-326.1万美元,同比去年增长53.57%
|
| 2021-04-26 |
股东大会：
将于2021-05-26召开股东大会
会议内容 ▼▲
- 1.Election of each of Keith McGovern and Stuart Woolf to our board of directors as Class II director to serve for the ensuing three years and until his or her successor is elected;
2.To ratify the selection by the Audit Committee of our board of directors of Marcum LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2021;
3.To approve an amendment to our Certificate of Incorporation to effect a reverse stock split of our outstanding common stock at a ratio of not less than one-for-five (1:5) and not more than one-for-fifteen (1:15), which exact ratio will be selected at the discretion of our board of directors, and provided that our board of directors may abandon the reverse stock split in its sole discretion;
4.To transact other business that may properly come before the annual meeting or any adjournments or postponements thereof.
|
| 2021-03-23 |
详情>>
业绩披露：
2020年年报每股收益-0.14美元,归母净利润-2016.8万美元,同比去年增长45.75%
|
| 2020-11-09 |
详情>>
业绩披露：
2020年三季报(累计)每股收益-0.11美元,归母净利润-1595.7万美元,同比去年增长40.97%
|
| 2020-09-25 |
股东大会：
将于2020-10-29召开股东大会
会议内容 ▼▲
- 1.Election of each of Pamela G. Marrone, Ph.D., Robert A. Woods, and Yogesh Mago to our board of directors as Class I director to serve for the ensuing three years and until his or her successor is elected;
2.To ratify the selection by the audit committee of our board of directors of Marcum LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2020;
3.To approve an amendment to our Certificate of Incorporation to effect a reverse stock split of our outstanding common stock at a ratio of not less than one-for-five (1:5) and not more than one-for-fifteen (1:15), which exact ratio will be selected at the discretion of our board of directors, and provided that our board of directors may abandon the reverse stock split in its sole discretion;
4.To approve anti-dilution provisions in warrants issued in connection with the Warrant Exchange Agreement dated April 29, 2020 in accordance with Nasdaq Listing Rule 5635(d);
5.To consider a stockholder proposal, if properly presented at the Annual Meeting;
6.To transact other business that may properly come before the Annual Meeting or any adjournments or postponements thereof.
|
| 2020-08-10 |
详情>>
业绩披露：
2020年中报每股收益-0.07美元,归母净利润-989.4万美元,同比去年增长7.26%
|
| 2020-05-11 |
详情>>
业绩披露：
2020年一季报每股收益-0.05美元,归母净利润-702.4万美元,同比去年增长-79.32%
|
| 2020-03-16 |
详情>>
业绩披露：
2019年年报每股收益-0.32美元,归母净利润-3717.5万美元,同比去年增长-83.92%
|
| 2019-04-30 |
股东大会：
将于2019-05-30召开股东大会
会议内容 ▼▲
- 1.Election of each of George H. Kerckhove and Zachary S. Wochok, Ph.D. to our board of directors as Class III director to serve for the ensuing three years and until his successor is elected;
2.To hold a non-binding, advisory vote to approve the compensation of the Company’s Named Executive Officers;
3.To hold a non-binding, advisory vote to recommend whether a non-binding stockholder vote to approve the compensation of the Company’s Named Executive Officers should occur every one, two or three years;
4.To approve the Company’s 2019 Employee Stock Purchase Plan;
5.Ratification of the selection by the audit committee of our board of directors of Marcum LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2019;
6.To transact other business that may properly come before the Annual Meeting or any adjournments or postponements thereof.
|
| 2018-04-30 |
股东大会：
将于2018-05-30召开股东大会
会议内容 ▼▲
- 1.Election of Richard Rominger to our board of directors as Class II director to serve for the ensuing three years and until his successor is elected.
2.Approval of an increase to the maximum aggregate number of shares authorized under the Marrone Bio Innovations, Inc. 2013 Stock Incentive Plan by 3,500,000 to 14,452,472 shares, in accordance with Nasdaq Listing Rule 5635(c).
3.Ratification of the selection by the audit committee of our board of directors of Marcum LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2018.
|
| 2018-01-03 |
股东大会：
将于2018-01-31召开股东大会
会议内容 ▼▲
- 1.Election of Pamela G. Marrone, Ph.D., our Chief Executive Officer, to our board of directors as a Class I director to serve for the ensuing three years and until her successor is elected.
2.Ratification of the selection by the audit committee of our board of directors of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2017.
3.Approval of the issuance of shares of our common stock and warrants to purchase shares of our common stock in connection with a private placement and related debt refinancing transactions in accordance with Listing Rule 5635(d) of The Nasdaq Stock Market LLC, or Nasdaq.
4.Approval of the issuance of shares of our common stock and warrants to purchase shares of our common stock to Ospraie Ag Science LLC, in accordance with Nasdaq Listing Rule 5635(b).
5.Approval of an increase to the number of shares authorized under the Marrone Bio Innovations, Inc. 2013 Stock Incentive Plan, or the 2013 Plan, by 4,000,000 to 10,952,472 shares, and to approve the 2013 Plan for purposes of Section 162(m)(4)(C) of the Internal Revenue Code of 1986, as amended.
6.Consideration of a stockholder proposal, if properly presented at the annual meeting.
|
| 2016-07-15 |
复牌提示：
2016-07-14 10:01:38 停牌，复牌日期 2016-07-14 10:06:38
|
| 2016-04-25 |
股东大会：
将于2016-05-25召开股东大会
会议内容 ▼▲
- 1.Election of our board’s two nominees for Class III directors to serve for the ensuing three years and until their successors are elected.
2.Ratification of the selection by the audit committee of our board of directors of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2016.
|
| 2015-11-16 |
股东大会：
将于2015-12-17召开股东大会
会议内容 ▼▲
- 1.Election of our board’s two nominees for Class II directors to serve for the ensuing three years and until their successors are elected.
2.Ratification of the selection by the audit committee of our board of directors of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2015.
|
| 2014-04-25 |
股东大会：
将于2014-05-29召开股东大会
会议内容 ▼▲
- 1. Election of our board’s two nominees for Class I directors to serve for the ensuing three years and until their successors are elected.
2. Ratification of the selection by the audit committee of our board of directors of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2014.
|